Skip to main content

Main menu

  • Home
  • About the Journal
    • General Information
    • Scope
    • Editorial Board
    • Benefits of Publishing
    • Impact & Metrics
    • Advertising/Sponsorship
    • About the Biochemical Society
  • Current Issue
  • For Authors
    • Submit Your Paper
    • Submission Guidelines
    • Editorial Policy
    • Open Access Policy
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • For Librarians
    • Open Access Policy
    • Terms and Conditions
      • Biochemical Journal- Terms and Conditions of Usage
      • Bioscience Reports- Terms and Conditions of Usage
  • For Readers
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • Collections
  • Help
    • Technical Support
    • Contact Us
  • Other Publications
    • Biochemical Journal
    • Clinical Science
    • Bioscience Reports
    • Neuronal Signaling
    • Biochemical Society Transactions
    • Essays in Biochemistry
    • Emerging Topics in Life Sciences
    • Biochemical Society Symposia
    • Cell Signalling Biology
    • Glossary of Biochemistry and Molecular Biology
    • The Biochemist
    • Biochemical Society

User menu

  • Log-in
  • Subscribe
  • Contact Us
  • Log out

Search

  • Advanced search
  • Other Publications
    • Biochemical Journal
    • Clinical Science
    • Bioscience Reports
    • Neuronal Signaling
    • Biochemical Society Transactions
    • Essays in Biochemistry
    • Emerging Topics in Life Sciences
    • Biochemical Society Symposia
    • Cell Signalling Biology
    • Glossary of Biochemistry and Molecular Biology
    • The Biochemist
    • Biochemical Society

Log-in

Sign-up for alerts  
  • My Cart
Bioscience Reports
Browse Archive
Advanced Search
  • Home
  • About the Journal
    • General Information
    • Scope
    • Editorial Board
    • Benefits of Publishing
    • Impact & Metrics
    • Advertising/Sponsorship
    • About the Biochemical Society
  • Current Issue
  • For Authors
    • Submit Your Paper
    • Submission Guidelines
    • Editorial Policy
    • Open Access Policy
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • For Librarians
    • Open Access Policy
    • Terms and Conditions
  • For Readers
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • Collections
  • Help
    • Technical Support
    • Contact Us

Research Article

Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis

Shenghua Chen, Yangzhang Tang, Xueyin Zhou
Bioscience Reports Feb 05, 2019, 39 (2) BSR20181761; DOI: 10.1042/BSR20181761
Shenghua Chen
Health Service Centre of West Street Coummunity of Xiangshan District, Huaibei 235000, Anhui Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
  • For correspondence: chenshenghuahb@sina.com
Yangzhang Tang
Department of Internal Cardiovascular Medicine of the People’s Hospital, Huaibei 235000, Anhui Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
Xueyin Zhou
Health Service Centre of West Street Coummunity of Xiangshan District, Huaibei 235000, Anhui Province, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
  • Article
  • Figures
  • Info & Metrics
  • Supplementary Data
  • PDF
Loading

Abstract

Circulating cystatin C (cys-C/CYC) has been identified as an independent predictor of all-cause mortality in patients with coronary artery disease and the general population. This meta-analysis aimed to systematically evaluate the association between elevated cys-C level and all-cause mortality and rehospitalization risk amongst patients with heart failure (HF). PubMed and Embase databases were searched until December 2017. All prospective observational studies that reported a multivariate-adjusted risk estimate of all-cause mortality and/or rehospitalization for the highest compared with lowest cys-C level in HF patients were included. Ten prospective studies involving 3155 HF patients were included. Meta-analysis indicated that the highest compared with lowest cys-C level was associated with an increased risk of all-cause mortality (hazard ratio (HR): 2.33; 95% confidence intervals (CI): 1.67–3.27; I2 = 75.0%, P<0.001) and combination of mortality/rehospitalization (HR: 2.06; 95%CI: 1.58–2.69; I2 = 41.6%, P=0.181). Results of stratified analysis indicated that the all-cause mortality risk was consistently found in the follow-up duration, cys-C cut-off value or type of HF subgroup. Elevated cys-C level is possibly associated with an increased risk of all-cause mortality and rehospitalization in HF patients. This increased risk is probably independent of creatinine or estimated glomerular filtration rate (eGFR).

  • all-cause mortality
  • cystatin C
  • heart failure
  • meta-analysis

Introduction

Heart failure (HF) is a global healthcare burden with unacceptable risk of morbidity, rehospitalization, and mortality [1,2]. According to the different pathophysiological mechanisms, patients are commonly classified into HF with preserved ejection fraction (EF) (HFpEF) or HF with reduced EF (HFrEF). HFpEF is associated with poor clinical outcomes and severe cardiovascular dysfunction [3,4]. Frequent hospitalization and prolonged hospital stay were the typical features of patients with HF [5,6]. HFpEF patients had a higher incidence of non-HF hospitalizations, while HFrEF patients had a higher incidence of HF hospitalizations [7]. Therefore, early prognostic stratification of HF patients at high risk of mortality and rehospitalization is in urgent need.

Biomarkers are frequently used to predict adverse outcomes in patients with HF [8]. HF may lead to renal dysfunction and cardiorenal syndrome through low cardiac output, accelerated atherosclerosis, inflammation, and increased venous pressure [9]. Renal function offers valuable information for the prognostic classification of patients with stable or decompensated HF [10]. HF patients with renal impairment represent a high-risk group with an approximately 50% greater risk of mortality than those with normal renal function [11]. Use of serum creatinine and creatinine-based formula to quantitate renal function is routinely applied in clinical practice. However, age, gender, muscle mass, physical activity, or diet can influence creatinine level [12].

Cystatin C (cys-C) is a small protein molecule producing by virtually all nucleated cells in the human body. Circulating cys-C level has been introduced as a more sensitive biomarker of early renal impairment [13], particularly in those with a normal creatinine level [14]. Several studies reported the association between cys-C level and all-cause mortality/rehospitalization risk amongst HF patients. However, no previous meta-analysis has been conducted to systematically evaluate the prognostic significance of cys-C level in HF patients. Nevertheless, the magnitude of the prognostic value varied considerably across studies.

In the current study, we performed a meta-analysis of prospective studies to qualitatively evaluate the prognostic value of cys-C level amongst HF patients in terms of all-cause mortality and/or rehospitalization.

Methods

Search strategy

We conducted and reported this meta-analysis in accordance with the checklists of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15]. Ethical approval is unnecessary as the present study does not contain individual patients data. PubMed and Embase databases were searched until December 2017 using the following keywords: ‘cystatin C’ AND ‘heart failure’ AND ‘mortality’ OR ‘death’ AND ‘prospective’ OR ‘follow-up’. No language restriction was applied. In addition, we also manually searched the reference lists of relevant articles to identify any additional studies.

Study selection

The full-text articles meeting the following inclusion criteria were selected: (i) prospective observational studies enrolling the HF patients; (ii) baseline circulating cys-C level as exposure; (iii) outcome measures were all-cause mortality and/or rehospitalization; and (iv) provided multivariate-adjusted risk estimate of all-cause mortality and/or rehospitalization for the highest compared with the lowest category of cys-C level. Exclusion criteria were: (i) study design was a retrospective or conference abstract; (ii) participants were not HF patients; and (iii) multiple articles from the same study population.

Data extraction and quality assessment

Two authors independently extracted data from included studies. Data extracted included the first author’s last name, publication year, country of origin, study design, patients’ number, age, proportion of men, comparison of cys-C cut-off value, outcome measure, event number, most fully adjusted hazard ratio (HR) or risk ratio (RR) and 95% confidence intervals (CI), follow-up period, and adjusted covariates. Any differences between the two authors were resolved by consultation with a third author. The methodological quality of the included studies was assessed by a 9-star Newcastle–Ottawa Scale (NOS) for cohort studies [16]. Based on this scale, studies with a rating of >7 stars were grouped as good quality.

Statistical analyses

All the meta-analyses were performed using STATA version 12.0 (StataCorp, TX, U.S.A.). We pooled the HR with 95% CI for the highest compared with the lowest cys-C level. Heterogeneity was evaluated using the I2 statistic and Cochrane Q test. The I2 statistic > 50% or P<0.10 of the Cochran Q test was considered the presence of significant heterogeneity. We chose a random-effect model when significant heterogeneity was present; otherwise, a fixed-effect model was applied. Subgroup analyses were performed according to region (Europe compared with others), follow-up duration (>1.5 compared with <1.5 years), sample sizes (≥400 compared with <400), type of HF (acute compared with chronic), and cys-C cut-off value. Sensitivity analysis was conducted by sequentially removing any one study at each turn to observe the reliability of the pooled risk estimate. In addition, we assessed the publication bias using the Egger’s linear regression test [17] and Begg’s rank correlation [18].

Results

Literature search and study characteristics

Figure 1 describes the flow chart of the study selection process. In brief, a total of 344 potentially relevant articles were identified in our initial literature search. After screening the titles and abstracts, 289 articles were excluded. The remaining 45 articles were determined for a detailed evaluation. Thirty-five articles were further removed mainly because they did not report the outcome of interest, conference abstract or reported outcome as continuous cys-C value. Thus, ten studies [19–28] were finally included in this meta-analysis.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Flow chart of the study selection process

Table 1 summarizes the main characteristics of the included studies. Sample sizes ranged between 162 and 2278 in individual studies. Seven studies [20,22–25,27,28] were conducted in Europe, two studies [19,21] in U.S.A., and one study [26] in China. Follow-up duration ranged from 12 months to 6.5 years. Different cut-off levels were used for defining cys-C elevation. Overall methodological quality of the included studies was moderate to good (ranging from 5 to 7 stars) on a 9-star NOS.

View this table:
  • View inline
  • View popup
Table 1 Summary of clinical studies included in meta-analysis

All-cause mortality

Nine studies [19–21,23–28] reported the prognostic value of the elevated cys-C level with all-cause mortality risk. As shown in Figure 2, meta-analysis showed that cys-C level was associated with greater risk of all-cause mortality (HR: 2.33; 95% CI: 1.67–3.27) for the highest compared with lowest cys-C category in a random-effect model, with evidence of significant heterogeneity (I2 = 75.0%, P<0.001). Sensitivity analyses showed minimal changes in magnitude of the pooled risk estimate when any one study was removed from the meta-analysis (Supplementary Table S1). Subgroup analyses suggested that prognostic values were consistently found in each named subgroup (Table 2). Publication bias was observed in the Egger’s test (P=0.016) but not Begg’s test (P=0.118). However, the result for publication bias is potentially unreliable because the number of studies analyzed was less than the recommended arbitrary minimum number of ten [29].

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Forest plot showing HR and 95% CI of all-cause mortality for the highest compared with the lowest category of cys-C level in a random-effect model
View this table:
  • View inline
  • View popup
Table 2 Subgroup analyses of all-cause mortality

Combination of mortality/rehospitalization

Three studies [21–23] reported the association between the elevated cys-C level and the combination of mortality/rehospitalization risk. As shown in Figure 3, meta-analysis indicated that cys-C level was associated with higher risk of combination of mortality/rehospitalization risk (HR: 2.06; 95% CI: 1.58–2.69) for the highest compared with lowest cys-C category in a fixed-effect model, without evidence of significant heterogeneity (I2 = 41.6%, P=0.181). Sensitivity analyses indicated that removal of any one study did not significantly change the conclusion (Supplementary Table S2).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3 Forest plot showing HR and 95% CI of combination of mortality/rehospitalization for the highest compared with the lowest category of cys-C level in a fixed-effect model

Discussion

This meta-analysis suggested that elevated cys-C level was possibly associated with an increased risk of all-cause mortality and rehospitalization in patients with HF. This increased risk may be independent of creatinine or urea nitrogen. HF patients with the higher category of cys-C level had a 2.3-fold greater risk of all-cause mortality. These findings are expected to improve the stratification of HF patients at higher risk of mortality and rehospitalization. This meta-analysis further reinforces the prognostic value of cys-C in patients with HF.

Subgroup analyses indicated that studies reporting single dichotomous cut-off value of cys-C level showed a similar high risk estimate, revealing even moderate increase in cys-C level could predict mortality risk of HF patients. The prognostic value of cys-C weakened with the lengthening of the follow-up period. This result may be explained that higher short-term mortality mainly reflects the worse heart function rather than renal dysfunction.

To the best of our knowledge, no previous meta-analysis has evaluated the prognostic significance of cys-C in HF patients. The finding of the current meta-analysis highlights that evaluation of renal function using cys-C should play an important role in risk stratification of this population. In clinical practice, renal function is usually detected using serum creatinine-based formula or Cockcroft–Gault estimate. However, both of them may lead to overestimation or underestimation of renal dysfunction [30]. cys-C is freely filtered by the glomerular membrane without secretion or reabsorption to the blood flow [31], so cys-C level is a sensitive marker of early kidney function [32,33]. Shlipak et al. [19] reported that cys-C level was a superior predictor of mortality than creatinine in elderly patients with chronic HF. Furthermore, higher cys-C level was associated with higher risk of all-cause mortality even in individuals with the normal estimated glomerular filtration rate (eGFR) [34,35]. These data revealed that elevated cys-C level for predicting all-cause mortality risk may be independent of serum creatinine in these populations. A previous meta-analysis [36] summarized that in the general population, individuals with the highest cys-C level had a 72% higher risk of all-cause mortality. Another well-designed meta-analysis [37] showed that elevated circulating cys-C significantly increased by 2.27-fold greater risk of all-cause mortality in people with suspected or established coronary artery disease.

A number of studies that did not satisfy our predefined inclusion criteria for this meta-analysis also evaluated the prognostic role of cys-C in HF patients. Results from the ASCEND-HF trial showed higher baseline but not follow-up cys-C level was associated with an increased risk of 30-day adverse events and 180-day all-cause mortality [38]. A retrospective study suggested that cys-C could be better prognostic biomarker for combination of recurrent HF or cardiac death when compared with N-terminal pro-B-type natriuretic peptide [39]. Measurement of cys-C level could improve early risk stratification of cardiac death in acute HF patients with normal to moderately impaired renal function [40]. Furthermore, the prognostic value of cys-C in HF patients was also supported by the continuous variable analysis (per SD increase) [41,42]. These data suggest that prognostic value of cys-C may be a superior biomarker in risk stratification of HF patients with normal or slightly impaired renal function.

Several limitations should be mentioned in this meta-analysis. First, inflammatory status, hyperthyroidism, glucocorticoids use, and current smoking status could have influenced cys-C level [43–45]. Lack of adjustment of these residual or unmeasured confounding factors may have overestimated the risk estimate. Second, cys-C level was determined only at baseline which may have caused misclassification of patients in each category of cys-C level. Follow-up monitoring of cys-C level may be more accurate for identifying patients who at particularly high adverse outcomes.Third, cut-off values of cys-C level in each study were different and we could not recommend appropriate cys-C level in clinical application. Fourth, publication bias test may be unreliable because the number of studies was less than the recommended arbitrary minimum number. Fifth, we did not use the continuous data to analyze the prognostic value of cys-C level due to limited studies reporting such data. Finally, generalizability of the current findings to younger HF patients should be with caution because this meta-analysis predominantly included older patients.

In conclusion, elevated circulating level of cys-C is possibly independently associated with an increased risk of all-cause mortality and rehospitalization in HF patients. Determination of cys-C level may improve classification of adverse outcomes in HF patients and help the clinician in therapeutic decision making.

Author contribution

S.C. contributed to study conception, results interpretation, language editing, and approval of the final version manuscript. Y.T. and X.Z. contributed to literature search, data extraction, quality assessment, and statistical analysis. Y.T. drafted the manuscript.

Funding

The authors declare that there are no sources of funding to be acknowledged.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Abbreviations: BMI, body mass index; BNP, B-type natriuretic peptide; CI, confidence interval; COPD, chronic obstructive pulmonary disease; cys-C/CYC, cystatin C; EF, ejection fraction; HF, heart failure; HFpEF, HF with preserved EF; HFrEF, HF with reduced EF; HR, hazard ratio; LVEF, left ventricular EF; NOS, Newcastle–Ottawa Scale; NP, not reported; NT-proBNP, N-terminal pro-BNP; SBP, systolic blood pressure

  • © 2019 The Author(s).
http://creativecommons.org/licenses/by/4.0/

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

References

  1. ↵
    1. Roger V.L.,
    2. Weston S.A.,
    3. Redfield M.M.,
    4. Hellermann-Homan J.P.,
    5. Killian J.,
    6. Yawn B.P.
    (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292, 344–350 doi:10.1001/jama.292.3.344 pmid:15265849
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Butrous H.,
    2. Hummel S.L.
    (2016) Heart failure in older adults. Can. J. Cardiol. 32, 1140–1147 doi:10.1016/j.cjca.2016.05.005 pmid:27476982
    OpenUrlCrossRefPubMed
  3. ↵
    1. Campbell R.T.,
    2. Jhund P.S.,
    3. Castagno D.,
    4. Hawkins N.M.,
    5. Petrie M.C.,
    6. McMurray J.J.
    (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J. Am. Coll. Cardiol. 60, 2349–2356 doi:10.1016/j.jacc.2012.04.064 pmid:23141494
    OpenUrlFREE Full Text
  4. ↵
    1. Mohammed S.F.,
    2. Borlaug B.A.,
    3. Roger V.L.,
    4. Mirzoyev S.A.,
    5. Rodeheffer R.J.,
    6. Chirinos J.A.
    (2012) Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ. Heart Fail. 5, 710–719 doi:10.1161/CIRCHEARTFAILURE.112.968594 pmid:23076838
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Gheorghiade M.,
    2. Vaduganathan M.,
    3. Fonarow G.C.,
    4. Bonow R.O.
    (2013) Rehospitalization for heart failure: problems and perspectives. J. Am. Coll. Cardiol. 61, 391–403 doi:10.1016/j.jacc.2012.09.038 pmid:23219302
    OpenUrlFREE Full Text
  6. ↵
    1. Wright S.P.,
    2. Verouhis D.,
    3. Gamble G.,
    4. Swedberg K.,
    5. Sharpe N.,
    6. Doughty R.N.
    (2003) Factors influencing the length of hospital stay of patients with heart failure. Eur. J. Heart Fail. 5, 201–209 doi:10.1016/S1388-9842(02)00201-5 pmid:12644013
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Ather S.,
    2. Chan W.,
    3. Bozkurt B.,
    4. Aguilar D.,
    5. Ramasubbu K.,
    6. Zachariah A.A.
    (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J. Am. Coll. Cardiol. 59, 998–1005 doi:10.1016/j.jacc.2011.11.040 pmid:22402071
    OpenUrlFREE Full Text
  8. ↵
    1. Mallick A.,
    2. Januzzi J.L. Jr.
    (2015) Biomarkers in acute heart failure. Rev. Esp. Cardiol. 68, 514–525 doi:10.1016/j.recesp.2015.02.009
    OpenUrlCrossRefPubMed
  9. ↵
    1. Cole R.T.,
    2. Masoumi A.,
    3. Triposkiadis F.,
    4. Giamouzis G.,
    5. Georgiopoulou V.,
    6. Kalogeropoulos A.
    (2012) Renal dysfunction in heart failure. Med. Clin. North Am. 96, 955–974 doi:10.1016/j.mcna.2012.07.005 pmid:22980058
    OpenUrlCrossRefPubMed
  10. ↵
    1. Perez Calvo J.I.,
    2. Josa Laorden C.,
    3. Gimenez Lopez I.
    (2017) Renal function assessment in heart failure. Rev. Clin. Esp. 217, 267–288 pmid:28258719
    OpenUrlPubMed
  11. ↵
    1. Smith G.L.,
    2. Lichtman J.H.,
    3. Bracken M.B.,
    4. Shlipak M.G.,
    5. Phillips C.O.,
    6. DiCapua P.
    (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. 47, 1987–1996 doi:10.1016/j.jacc.2005.11.084 pmid:16697315
    OpenUrlFREE Full Text
  12. ↵
    1. Hsu C.Y.,
    2. Chertow G.M.,
    3. Curhan G.C.
    (2002) Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 61, 1567–1576 doi:10.1046/j.1523-1755.2002.00299.x pmid:11967006
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Mussap M.,
    2. Plebani M.
    (2004) Biochemistry and clinical role of human cystatin C. Crit. Rev. Clin. Lab. Sci. 41, 467–550 doi:10.1080/10408360490504934 pmid:15603510
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Shimizu-Tokiwa A.,
    2. Kobata M.,
    3. Io H.,
    4. Kobayashi N.,
    5. Shou I.,
    6. Funabiki K.
    (2002) Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 92, 224–226 doi:10.1159/000064453 pmid:12187109
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Liberati A.,
    2. Altman D.G.,
    3. Tetzlaff J.,
    4. Mulrow C.,
    5. Gotzsche P.C.,
    6. Ioannidis J.P.
    (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 62, e1–34 doi:10.1016/j.jclinepi.2009.06.006 pmid:19631507
    OpenUrlCrossRefPubMed
  16. ↵
    1. Wells G.,
    2. Shea B.,
    3. O’Connell D.,
    4. Peterson J.,
    5. Welch V.,
    6. Losos M.
    (2018) The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed online: 1 October 2018
  17. ↵
    1. Egger M.,
    2. Davey Smith G.,
    3. Schneider M.,
    4. Minder C.
    (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 doi:10.1136/bmj.315.7109.629 pmid:9310563
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Begg C.B.,
    2. Mazumdar M.
    (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 doi:10.2307/2533446 pmid:7786990
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Shlipak M.G.,
    2. Katz R.,
    3. Fried L.F.,
    4. Jenny N.S.,
    5. Stehman-Breen C.,
    6. Newman A.B.
    (2005) Cystatin-C and mortality in elderly persons with heart failure. J. Am. Coll. Cardiol. 45, 268–271 doi:10.1016/j.jacc.2004.09.061 pmid:15653026
    OpenUrlFREE Full Text
  20. ↵
    1. Lassus J.,
    2. Harjola V.P.,
    3. Sund R.,
    4. Siirila-Waris K.,
    5. Melin J.,
    6. Peuhkurinen K.
    (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur. Heart J. 28, 1841–1847 doi:10.1093/eurheartj/ehl507 pmid:17289743
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Campbell C.Y.,
    2. Clarke W.,
    3. Park H.,
    4. Haq N.,
    5. Barone B.B.,
    6. Brotman D.J.
    (2009) Usefulness of cystatin C and prognosis following admission for acute heart failure. Am. J. Cardiol. 104, 389–392 doi:10.1016/j.amjcard.2009.03.059 pmid:19616673
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Manzano-Fernandez S.,
    2. Januzzi J.L. Jr.,
    3. Boronat-Garcia M.,
    4. Bonaque-Gonzalez J.C.,
    5. Truong Q.A.,
    6. Pastor-Perez F.J.
    (2011) beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J. Am. Coll. Cardiol. 57, 849–858 doi:10.1016/j.jacc.2010.08.644 pmid:21310322
    OpenUrlFREE Full Text
  23. ↵
    1. Carrasco-Sanchez F.J.,
    2. Galisteo-Almeda L.,
    3. Paez-Rubio I.,
    4. Martinez-Marcos F.J.,
    5. Camacho-Vazquez C.,
    6. Ruiz-Frutos C.
    (2011) Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J. Card. Fail. 17, 31–38 doi:10.1016/j.cardfail.2010.07.248 pmid:21187262
    OpenUrlCrossRefPubMed
  24. ↵
    1. Perez-Calvo J.I.,
    2. Ruiz-Ruiz F.J.,
    3. Carrasco-Sanchez F.J.,
    4. Morales-Rull J.L.,
    5. Manzano-Fernandez S.,
    6. Galisteo-Almeda L.
    (2012) Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur. J. Intern. Med. 23, 599–603 doi:10.1016/j.ejim.2012.06.002 pmid:22939803
    OpenUrlCrossRefPubMed
  25. ↵
    1. Carrasco-Sanchez F.J.,
    2. Perez-Calvo J.I.,
    3. Morales-Rull J.L.,
    4. Galisteo-Almeda L.,
    5. Paez-Rubio I.,
    6. Baron-Franco B.
    (2014) Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels. J. Cardiovasc. Med. 15, 115–121 doi:10.2459/JCM.0b013e3283654bab pmid:24522084
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ruan Z.B.,
    2. Zhu L.,
    3. Yin Y.G.,
    4. Chen G.C.
    (2014) Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome. J. Res. Med. Sci. 19, 404–409 pmid:25097621
    OpenUrlPubMed
  27. ↵
    1. Jackson C.E.,
    2. Haig C.,
    3. Welsh P.,
    4. Dalzell J.R.,
    5. Tsorlalis I.K.,
    6. McConnachie A.
    (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur. J. Heart Fail. 18, 1491–1498 doi:10.1002/ejhf.543 pmid:27114189
    OpenUrlCrossRefPubMed
  28. ↵
    1. Breidthardt T.,
    2. Sabti Z.,
    3. Ziller R.,
    4. Rassouli F.,
    5. Twerenbold R.,
    6. Kozhuharov N.
    (2017) Diagnostic and prognostic value of cystatin C in acute heart failure. Clin. Biochem. 50, 1007–1013 doi:10.1016/j.clinbiochem.2017.07.016 pmid:28756070
    OpenUrlCrossRefPubMed
  29. ↵
    1. Lau J.,
    2. Ioannidis J.P.,
    3. Terrin N.,
    4. Schmid C.H.,
    5. Olkin I.
    (2006) The case of the misleading funnel plot. BMJ 333, 597–600 doi:10.1136/bmj.333.7568.597 pmid:16974018
    OpenUrlFREE Full Text
  30. ↵
    1. Kemperman F.A.,
    2. Krediet R.T.,
    3. Arisz L.
    (2002) Formula-derived prediction of the glomerular filtration rate from plasma creatinine concentration. Nephron 91, 547–558 doi:10.1159/000065012 pmid:12138254
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Filler G.,
    2. Bokenkamp A.,
    3. Hofmann W.,
    4. Le Bricon T.,
    5. Martinez-Bru C.,
    6. Grubb A.
    (2005) Cystatin C as a marker of GFR–history, indications, and future research. Clin. Biochem. 38, 1–8 doi:10.1016/j.clinbiochem.2004.09.025 pmid:15607309
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Zhang Z.,
    2. Lu B.,
    3. Sheng X.,
    4. Jin N.
    (2011) Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am. J. Kidney Dis. 58, 356–365 doi:10.1053/j.ajkd.2011.02.389 pmid:21601330
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Madero M.,
    2. Sarnak M.J.
    (2009) Association of cystatin C with adverse outcomes. Curr. Opin. Nephrol. Hypertens. 18, 258–263 doi:10.1097/MNH.0b013e328326f3dd pmid:19374014
    OpenUrlCrossRefPubMed
  34. ↵
    1. Wu C.K.,
    2. Lin J.W.,
    3. Caffrey J.L.,
    4. Chang M.H.,
    5. Hwang J.J.,
    6. Lin Y.S.
    (2010) Cystatin C and long-term mortality among subjects with normal creatinine-based estimated glomerular filtration rates: NHANES III (Third National Health and Nutrition Examination Survey). J. Am. Coll. Cardiol. 56, 1930–1936 doi:10.1016/j.jacc.2010.04.069 pmid:21109116
    OpenUrlFREE Full Text
  35. ↵
    1. Astor B.C.,
    2. Shafi T.,
    3. Hoogeveen R.C.,
    4. Matsushita K.,
    5. Ballantyne C.M.,
    6. Inker L.A.
    (2012) Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am. J. Kidney Dis. 59, 653–662 doi:10.1053/j.ajkd.2011.11.042 pmid:22305758
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Luo J.,
    2. Wang L.P.,
    3. Hu H.F.,
    4. Zhang L.,
    5. Li Y.L.,
    6. Ai L.M.
    (2015) Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis. Clin. Chim. Acta 450, 39–45 doi:10.1016/j.cca.2015.07.016 pmid:26192218
    OpenUrlCrossRefPubMed
  37. ↵
    1. Yang S.,
    2. Song L.,
    3. Zhao L.,
    4. Dong P.,
    5. Lai L.,
    6. Wang H.
    (2017) Predictive value of cystatin C in people with suspected or established coronary artery disease: a meta-analysis. Atherosclerosis 263, 60–67 doi:10.1016/j.atherosclerosis.2017.05.025 pmid:28599259
    OpenUrlCrossRefPubMed
  38. ↵
    1. Tang W.H.,
    2. Dupont M.,
    3. Hernandez A.F.,
    4. Voors A.A.,
    5. Hsu A.P.,
    6. Felker G.M.
    (2015) Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. JACC Heart Fail. 3, 40–49 doi:10.1016/j.jchf.2014.06.014 pmid:25453534
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Kim T.H.,
    2. Kim H.,
    3. Kim I.C.
    (2015) The potential of cystatin-C to evaluate the prognosis of acute heart failure: a comparative study. Acute Cardiac Care 17, 72–76 doi:10.1080/17482941.2016.1203440 pmid:27494366
    OpenUrlCrossRefPubMed
  40. ↵
    1. Naruse H.,
    2. Ishii J.,
    3. Kawai T.,
    4. Hattori K.,
    5. Ishikawa M.,
    6. Okumura M.
    (2009) Cystatin C in acute heart failure without advanced renal impairment. Am. J. Med. 122, 566–573 doi:10.1016/j.amjmed.2008.10.042 pmid:19393984
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Damman K.,
    2. van der Harst P.,
    3. Smilde T.D.,
    4. Voors A.A.,
    5. Navis G.,
    6. van Veldhuisen D.J.
    (2012) Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 98, 319–324 doi:10.1136/heartjnl-2011-300692 pmid:22038544
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Welsh P.,
    2. Kou L.,
    3. Yu C.,
    4. Anand I.,
    5. van Veldhuisen D.J.,
    6. Maggioni A.P.
    (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur. J. Heart Fail. 20, 268–277 doi:10.1002/ejhf.988;28960777
    OpenUrlCrossRef
  43. ↵
    1. Bokenkamp A.,
    2. van Wijk J.A.,
    3. Lentze M.J.,
    4. Stoffel-Wagner B.
    (2002) Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations. Clin. Chem. 48, 1123–1126 pmid:12089191
    OpenUrlFREE Full Text
  44. ↵
    1. Fricker M.,
    2. Wiesli P.,
    3. Brandle M.,
    4. Schwegler B.,
    5. Schmid C.
    (2003) Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 63, 1944–1947 doi:10.1046/j.1523-1755.2003.00925.x pmid:12675875
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Knight E.L.,
    2. Verhave J.C.,
    3. Spiegelman D.,
    4. Hillege H.L.,
    5. de Zeeuw D.,
    6. Curhan G.C.
    (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 65, 1416–1421 doi:10.1111/j.1523-1755.2004.00517.x pmid:15086483
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
Previous ArticleNext Article
Back to top

February 2019

Volume: 39 Issue: 2

  • Table of Contents
  • Index by author

Actions

Email

Thank you for your interest in spreading the word about Bioscience Reports.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis
(Your Name) has forwarded a page to you from Bioscience Reports
(Your Name) thought you would like to see this page from the Bioscience Reports web site.
Share
Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis
Shenghua Chen, Yangzhang Tang, Xueyin Zhou
Bioscience Reports Feb 2019, 39 (2) BSR20181761; DOI: 10.1042/BSR20181761
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Facebook logo Mendeley logo
Citation Tools
Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis
Shenghua Chen, Yangzhang Tang, Xueyin Zhou
Bioscience Reports Feb 2019, 39 (2) BSR20181761; DOI: 10.1042/BSR20181761

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts

Please log in to add an alert for this article.

Request Permissions
Save to my folders

View Full PDF

 Open in Utopia Docs
  • Tweet Widget
  • Facebook Like

Jump To

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Author contribution
    • Funding
    • Competing interests
    • References
  • Figures
  • Info & Metrics
  • Supplementary Data
  • PDF

Keywords

all-cause mortality
cystatin C
heart failure
Meta-analysis

Related Articles

Cited By...

  • Portland Press Homepage
  • Publish With Us
  • Advertising
  • Technical Support
  • Bioscience Reports
  • Biochemical Journal
  • Clinical Science
  • Neuronal Signaling
  • Essays in Biochemistry
  • Emerging Topics in Life Sciences
  • Biochemical Society Transactions
  • Biochemical Society Symposia
  • Cell Signalling Biology

Portland Press Limited
Charles Darwin House
12 Roger Street
London WC1N 2JU
Email: editorial@portlandpress.com

The Biochemical Society